Pharmaceutical dosage form for treatment of multiple sclerosis

Details Pharmaceutical dosage form for treatment of multiple sclerosis Pharmaceutical dosage form for treatment of multiple sclerosis

1995-05-31

1999-01-12

Achutamurthy, Ponnathapura

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

424451, 424464, 424474, 424489, 514 2, 514 12, 514 21, 514825, 514960, 514962, A61K 3900, A61K 3816, A61K 914, A61K 920

Patent

active

058583645

ABSTRACT:
The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

REFERENCES:
Weiner et al. Science: vol. 259, pp. 1321-1324, 1993.
Yoon. Science: vol. 259, p. 1263, 1993.
Stoffel et al: Proc. Soc. Natl. Acad. Sci. USA, vol. 81, pp. 5012-5016, 1984.
Unanue et al., Science, 236:551-557 (1987).
Mattingly et al., Jour. of Immunol., 125:1044-1047 (1980).
Holoshitz et al., Science, 219:56-58 (1983).
Whitaker, Jour. of Biol. Chem., 250:9106-9111 (1975).
Miller, FASEB, 5:2560-2566 (1991).
Phadke et al., Arthritis and Rheumatism, 27(7):797-806 (1984).
Braley-Mullen et al., Cellular Immunology, 5:408-413 (1980).
Salk et al., Studies of Myelin Basic Protein Administration in Multiple Sclerosis Patients, 419-427 (1984).
Ngan et al., J. Immunol., 120:861 (1978).
Gautam et al., J. Immunol., 135:2975 (1985).
Titus et al., Int. Arch. Allergy Appl. Immunol., 65:323 (1981).
Nagler-Anderson et al., Proc. Natl'l. Acad. Sci. USA, 83:7443-7446 (1986).
Swierkosz et al., J. Immunol., 119:1501 (1977).
Lando et al., Nature, 287:551 (1980).
Lando et al., J. Immunol., 126:1526 (1981).
Sriram et al., Cell. Immunol., 75:378 (1983).
Trauggot et al., J. Neurol. Sci., 56:65 (1982).
Raine et al., Lab. Invest., 48:275 (1983).
McKenna et al., Cell. Immu. 81:391 (1983).
Srejan et al., Cell. Immun., 84:171 (1984).
McKenna et al., Cell. Immun., 88:251 (1984).
Burns et al., Neurology, 36:92 (1986).
Belik et al., Vopr. Med. Khim., 24:372 (1978).
Braley-Mullen al., Cell. Immun., 39:289 (1978).
McDermott et al., J. Neuro. Sci. 46:137 (1980).
Raziuddin et al., J. Immunol., 128:2073 (1982).
Eylar et al., Nature, 236:74 (1972).
Lider et al., J. Immunol., 142:748 (1989).
Michael, Immunol. Invest., 18:1049-1054 (1989).
Wells, J. Infect. Dis., 9:147 (1911).
Alvord et al., Annals of Neurol., 6:461 (1979).
Alford et al., Annals of Neurol., 6:469 (1979).
Alford et al., Annals of Neurol., 6:474 (1979).
Higgins et al., J. Immunology, 140:440-445, 1988.
Eylar, Adv. Exp. Med. Bio., 98:259-281, 1978.
Schoen, J. Immounol., 128:717-719, 1982.
Higgins et al., Annals Neurology, abstract No. P154, 1986.
Whitacre et al., 6th Int'l . Cong. Immunol., abstract No. 3.62.21, 1986.
Zamvil et al., Nature, 324:258-260, 1986.
Fritz et al., J. Immunol., 134:2328-2332, 1985.
Fritz et al., J. Immunol., 130:191-194, 1983.
Pettinelli et al., J. Immunol., 129:1209-1211, 1982.
Thompson et al., Clin. Exp. Immunol., 64:581-586, 1985.
Friedman et al., PNAS, 91:6688-6692, 1994.
Bitar, dissertion entitled, The Suppressive Effects of Oral Myelin Basic Protein..., 1986.
Nagler-Anderson, dissertion entitled, Immunoregulation of Exp. Model of Autoimmunity, 1986.
Rothbart, 1st Forum in Virology, pp. 518-520, 1986.
Bitar et al., Cell. Immunol., 112:364-370, 1988.
Eylar et al., Neurochem. Research, 4:249-258, 1979.
Kagnoff, Oral Tolerance, pp. 248-269, 1982.
Mowat, Immunol. Today, 8:93-98, 1987.
Campbell et al., Arch. Neurol., 29:10-15, 1973.
Carnegie et al., Immunol. 19:55-63, 1970.
Fritz et al., J. Immunol. 130:1024-1026, 1983.
Hashim et al., Arch. Biochem. and Biophy., 156:287-297, 1973.
Lietch, G.J., Proceeding of the Society for Experimental Biology and Medicine, Apr. 1996, vol. 121 (4), pp. 1253-1256.

Affiliated with

Also associated with

Rating

Pharmaceutical dosage form for treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical dosage form for treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical dosage form for treatment of multiple sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1511941